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Objective: The aim of this study is to present a predictive model of Parkinson’s dis-
ease (PD) global severity, measured with the Clinical Impression of Severity Index for 
Parkinson’s Disease (CISI-PD).
Methods: This is an observational, longitudinal study with annual follow-up assessments 
over 3 years (four time points). A multilevel analysis and multiple imputation techniques 
were performed to generate a predictive model that estimates changes in the CISI-PD 
at 1, 2, and 3 years.
results: The clinical state of patients (CISI-PD) significantly worsened in the 3-year 
follow-up. However, this change was of small magnitude (effect size: 0.44). The following 
baseline variables were significant predictors of the global severity change: baseline 
global severity of disease, levodopa equivalent dose, depression and anxiety symptoms, 
autonomic dysfunction, and cognitive state. The goodness-of-fit of the model was ade-
quate, and the sensitive analysis showed that the data imputation method applied was 
suitable.
conclusion: Disease progression depends more on the individual’s baseline character-
istics than on the 3-year time period. Results may contribute to a better understanding 
of the evolution of PD including the non-motor manifestations of the disease.
Keywords: Parkinson’s disease, disease global severity, predictive model, multilevel analysis, multiple imputation
inTrODUcTiOn
Parkinson’s disease (PD) is a neurodegenerative, chronic, progressively disabling, and incurable 
disease, which occurs in about 2% of the population over 65 years old (1). From a clinical perspective, 
it is characterized by the onset of motor symptoms such as tremor, rigidity, bradykinesia, postural 
instability, and gait alterations (2).
In addition, PD presents a broad range of non-motor symptoms, which are equally or even more 
disabling than motor symptoms, appearing early stages of the disease or even in before diagnosis 
2
Ayala et al. Severity of PD
Frontiers in Neurology | www.frontiersin.org October 2017 | Volume 8 | Article 551
(3). Some non-motor symptoms are sleep alterations, mood and 
perception changes, attention and memory problems, cardiovas-
cular and gastrointestinal disorders, fatigue, urinary, and sexual 
function disorders (3).
Scales have been developed to measure specific aspects of 
PD, focusing on motor and non-motor symptoms. However, there 
are less global indices that provide a general view of the patient’s 
condition (4). A clinimetric index, the Clinical Impression of 
Severity Index of Parkinson’s Disease (CISI-PD) was published in 
2006 (4). This index provides information about the degree of 
severity of the patient which completes and summarizes the data 
obtained from other scales (5). Moreover, its simplicity and ease 
of use make it a very helpful tool in both clinical practice and 
research (5).
The CISI-PD may be considered an appropriate assessment 
of PD global severity. A recent study has demonstrated that 
this index performed better than other frequently used global 
evaluations coming from clinicians (CGIS) and patients (PGIS) 
(6). In comparison with the Hoehn and Yahr (HY), the CISI-PD 
correlated at a similar level with other measures of PD severity 
but offers specific information on four important aspects of the 
disease and is more precise (range of score: 0–24).
An international and multicenter study carried out to validate 
the CISI-PD showed that the main cross-sectional determinant 
factors of disease severity were the patient’s motor condition, 
disease duration, depression and, to a lesser extent, age and 
comorbidity (5). However, there is a lack of longitudinal studies 
using the CISI-PD that would allow finding its main predictors.
To address this deficit, we conducted a longitudinal study to 
assess how the evaluation of PD global severity, measured by the 
CISI-PD, changed over time. In addition, we developed a model 
of global severity to know which motor and non-motor baseline 
variables could predict PD global severity at 1, 2, and 3 years.
MaTerials anD MeThODs
Design
This was a multicenter, national, observational, and longitudinal 
study, with a baseline assessment and annual evaluations over 
3  years, and a total of four time points. The data collection 
involved a total of 23 neurologists from 21 hospitals distributed 
all over Spain.
Participants
A sample was selected from patients seen consecutively in the 
neurology or movement disorder departments of various hospi-
tals in Spain. The following inclusion criteria were applied: age 
equal or above 30 years; idiopathic PD diagnosis carried out by 
neurologists’ expert in movement disorders, according to the 
modified criteria of the Brain Bank of the UK Parkinson’s Disease 
Society (7); and having signed informed consent. Exclusion crite-
ria were the presence of medical or psychiatric comorbidity that 
would hinder an adequate assessment of PD.
This study was carried out in accordance with the recommen-
dations of Research Ethics Committee of the Carlos III Health 
Institute and the Clinical Research Ethics Committee of the La 
Princesa Hospital, Madrid. All subjects gave written informed 
consent in accordance with the Declaration of Helsinki.
The baseline evaluation included 389 patients with idiopathic 
PD and 205 completed the follow-up. The causes for case loss at 
follow-up were as follows: 52 due to inability of researchers to 
continue; 21 patients refused to remain in the study; 12 patients 
died; 10 patients moved; 7 patients changed diagnosis; 9 patients 
dropped out for other reasons (2 could not attend the visits; 2 
developed a cognitive impairment; 2 and other comorbidities 
that prevented follow-up; 2 were impossible to contact; 1 and 
changed specialist). In 73 cases, there were missing values in some 
questionnaire items.
assessments
All assessment instruments were specific for PD, except for the 
Hospital Anxiety and Depression Scale (HADS) (8) and the 
questionnaire EQ-5D with three response levels (EQ-5D-3L) (9), 
which are generic scales. Sociodemographic and clinical charac-
teristics were also recorded, including levodopa equivalent dose 
(LED) (9). Table S1 in Supplementary Material summarizes the 
scales applied in the study.
Self-assessment Instruments
The HADS is made of 14 items grouped into two subscales that 
evaluate the presence of anxiety and depression (8). Items are 
scored from 0 (no problem) to 3 (severe problem), and a score 
above 10 in each sub-scale indicates the presence of anxiety or 
depression, respectively. It can be used in the hospital and com-
munity environments, and its validity has been confirmed in 
patients with PD (10).
The SCales for Outcomes in PArkinson’s disease SCOPA-Sleep 
(11) is a scale comprising two sections that evaluate night-time 
sleep (SCOPA-NS) and daytime sleepiness (SCOPA-DS). The 
SCOPA-Autonomic (SCOPA-AUT) measures autonomic 
dysfunction in the following areas: gastrointestinal; urinary; 
cardiovascular; thermoregulatory; pupillomotor; and sexual 
dysfunction (male or female) (12). It is composed by 25 items, 
with score ranging from 0 (“never”) to 3 (“often”) and a maximum 
total score of 69, and the higher score, the worse autonomic 
dysfunction (13).
The EQ-5D-3L questionnaire is a tool that evaluates health-
related quality of life and health status (9). It provides an index 
whose value may range from 0, representing death, and 1, rep-
resenting the best health status, and it may have negative values 
that would represent a state “worse than death.” In addition, the 
EQ-5D-3L questionnaire contains a visual analog scale (EQ-VAS) 
assessing current health status. It is a useful scale in patients with 
PD (14, 15).
Instruments Administered by the Neurologist
The SCOPA-Cognition (SCOPA-COG) assesses four cognitive 
domains that are typically affected by the disease: memory (four 
items); attention (two items); executive function (three items); 
and visuospatial function (one item) (16). The maximum total 
score is 43, and a higher score reflects a better performance (16). 
The Parkinson’s Psychosis Rating Scale modified (PPRSm) is a 
scale that assesses the presence of psychotic symptoms in PD 
TaBle 1 | Descriptive analysis: complete vs. incomplete cases.
all respondents non respondents t-Test (p-value)
Mean/% sD N Mean/% sD N Mean/% sD
Gender (%)
Male 54.24% 108 52.68% 103 55.98% 0.515*
Female 45.76% 97 47.32% 81 44.02%
Age 65.92 11.15 205 63.71 10.71 184 68.39 11.14 <0.001
Disease duration (years) 8.11 6.00 205 7.67 5.65 184 8.59 6.34 0.131
LED 547.40 371.62 205 493.77 343.67 184 607.16 392.86 0.003
HADS total baseline 13.10 7.60 205 12.56 6.78 184 13.70 8.40 0.147
SCOPA-AUT total baseline 20.45 11.07 205 19.39 10.85 184 21.64 11.21 0.045
SCOPA-COG baseline 23.24 7.36 205 24.99 6.13 184 21.29 8.11 <0.001
CISI-PD Baseline 7.68 4.25 205 7.02 3.95 184 8.43 4.46 0.001
CISI-PD time 1 7.81 4.29 205 7.28 3.95 184 8.73 4.71 0.005
CISI-PD time 2 8.27 4.13 205 7.94 3.83 184 9.45 4.91 0.034
CISI-PD time 3 8.79 3.94 205 8.70 3.96 184 9.61 3.66 0.296
*p-Value of chi-square test.
CISI-PD, Clinical Impression of Severity Index of Parkinson’s Disease; LED, levodopa equivalent dose; HADS, Hospital Anxiety and Depression Scale; SCOPA-AUT,  
SCOPA-autonomic scale; SCOPA-COG, SCOPA-Cognition scale.
Bonferroni correction: p < 0.003.
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and comprises six items. Each item scores from 0 (“absent”) to 3 
(“severe”), and the higher score, the more severe the symptoms 
(17–19). The SCOPA-Motor is a tool that assesses the motor 
aspects of the disease and contains 21 items grouped in 3 sections 
(20): motor exploration (SCOPA-Motor EM), with 10 items; ADL 
(SCOPA-Motor ADL), made up of 7 items; and motor complica-
tions (SCOPA-Motor COMP) that contains 4 items. All items 
score range from 0 (“normal”) to 3 (“severe”), and the higher 
score, the greater the severity (20).
The CISI-PD is a clinimetric index that reflects the neurolo-
gist’s impression of the patient’s severity. It comprises four items 
(motor signs, disability, motor complications, and cognitive state) 
that are assessed by the neurologist after interview and clinical 
exam (4, 5). Each item ranges from 0 (“normal”) to 6 (“severe”); 
an index is obtained from the sum of these scores, ranging 0–24. 
Values of 1–7 represent mild disease, 8–14 moderate, and 15 or 
above severe PD (5).
The HY classification assesses motor alteration and disability 
in five stages. Stage 1 is mild, with unilateral symptoms and stage 
5 is the most severe, when the patient is bedridden or confined 
to a wheelchair (21).
Data analysis
First, we assessed whether there were important differences 
between individuals with and without missing data at follow-
up (22). For this purpose, chi-square and t-tests were applied 
comparing the groups that did and did not complete the study. 
The difference in the scores between time 0 (baseline) and time 3 
(third follow-up), taking only these two time points, was analyzed 
using paired-sample t-test or the Wilcoxon test (depending on 
whether or not they followed a normal distribution, respectively). 
Tables 1 and 2 list all variables assessed.
The changes in CISI-PD scores were studied with analysis of 
variance for repeated measures, taking time as a factor. All previ-
ous analysis were adjusted for multiple comparisons using the 
Bonferroni method (statistical significance p < 0.003). In addition, 
the effect size (d) was calculated to describe the magnitude of change 
of the CISI-PD throughout the study period. It was defined as the 
mean difference divided by the SD of baseline scores. In accordance 
with Cohen’s criteria, the magnitude of change was considered small 
if, when expressed as an absolute value, it fell between 0.2 ≤ d < 0.5; 
moderate, 0.5 ≤ d < 0.8; and large, d ≥ 0.8 (23).
To analyze the individual change in PD global severity (CISI-PD 
score), and taking into consideration the two-level hierarchical 
structure of the data, we performed a multilevel linear regression 
with random effects. Level 1 was made up of repeated measures 
and described each individual’s evolution over time, based on the 
following categories: T0  =  baseline; T1  =  1  year; T2  =  2  years; 
T3 = 3 years of follow-up. Level 2, made up of individuals, described 
the change in the trajectories between individuals and identified 
factors, which explain the differences between them (24). The first 
step entailed performance of a non-conditional or empty multilevel 
model, which contained no predictors. The second step involved 
the creation of a predictive model including the following variables 
measured at baseline: global severity status of the disease (CISI-PD), 
neuro-psychiatric measurements (HADS Total, PPRSm, SCOPA-
COG, SCOPA-Sleep), psychosocial measurements (EQ-5D-3L 
index), sociodemographic variables (age and sex), and clinical 
variables (disease duration; LED; EQ-VAS; SCOPA-Motor EM 
items bradykinesia, rigidity, tremor, and axial; and SCOPA-AUT). 
Since there were only three separate follow-up points in time, time 
was introduced in the model as a discrete variable.
We calculated the intraclass correlation coefficient (ICC) for 
both the empty and the predictive model, providing information 
on the proportion of variance due to differences across individuals. 
A stepwise backward regression (criterion: p < 0.05) was applied to 
remove the non-significant variables from the predictive model to 
get a model that meets the principle of parsimony, while ensuring 
absence of collinearity. This regression model presented 30.30% of 
losses in the outcome variable and 3.12% in the rest of variables 
with missing values. Missing data on CISI-PD at each of the follow-
up time point was: time 1, 17.2%; time 2, 32.4%; and time 3, 41.4%.
To deal with the possible bias resulting from patients lost to 
follow-up, data imputation was used on 33.42% of the cases (25). 
TaBle 2 | Changes in clinical variables between baseline and time 3 (n = 205).
Time 0 Time 3 t-Testa/
Wilcoxonb 
(p-value)Mean sD Mean sD
HADS-ANXIETY 7.17 4.02 7.03 4.27 N.S.a
HADS-DEPRESSION 5.46 3.62 5.95 3.96 N.S.a
HADS total 12.64 6.79 12.99 7.48 N.S.a
SCOPA-NS 5.36 4.05 4.59 3.44 N.S.a
SCOPA-DS 3.69 3.12 3.77 2.90 N.S.a
SCOPA-AUT total 17.83 9.62 20.99 9.83 <0.001a
EQ-5D index  0.71 0.25 0.65 0.28 <0.001a
EQ-VAS 64.06 19.89 60.22 18.21 N.S.a
SCOPA-COG 24.91 6.14 24.50 7.30 N.S.a
PPRSm 1.07 1.47 1.24 1.58 N.S.b
SCOPA-MOTOR EM 7.38 4.46 8.80 5.10 <0.001a
SCOPA-MOTOR ADL 5.00 3.00 6.57 3.89 <0.001a
SCOPA-MOTOR COMP 2.09 2.80 2.74 2.70 <0.001b
SCOPA-MOTOR total 14.51 7.72 18.05 9.14 <0.001a
CISI-PD 6.98 3.91 8.71 3.98 <0.001a
aT-Test.
bWilcoxon.
N.S., non-significant difference; SCOPA-MOTOR EM, SCOPA-motor exploration 
scale; SCOPA-MOTOR ADL, SCOPA scale on activities of daily life; SCOPA-MOTOR 
COMP, SCOPA-motor complications scale; SCOPA-MOTOR Total, total motor score; 
SCOPA-NS, SCOPA night-time sleep scale; SCOPA-DS, SCOPA daytime sleepiness 
scale; SCOPA-AUT Total, total score of SCOPA scale of autonomic symptomatology; 
SCOPA-COG, SCOPA Cognitive scale; CISI-PD, Clinical Impression of Severity Index 
of Parkinson’s Disease; HADS, Hospital Anxiety and Depression Scale; PPRSm, 
Parkinson’s Psychosis rating Scale modified; EQ-5D Index, index of EQ-5D Quality of 
Life questionnaire; EQ-VAS, analog visual scale of EQ-5D.
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Due to the missing values that were found in the outcome variable 
(CISI-PD at follow-up), a “multiple imputation, then deletion” 
(MID) procedure was developed (26, 27). In this method, the 
cases with imputed outcome variable are excluded. In addition, a 
sensitivity analysis was performed to assess the suitability of the 
imputation models. For this purpose, MID was compared with a 
model with missing values and a multiple imputation by chained 
equations, expecting similar results in the three models.
The predictions were obtained through Monte Carlo simulation. 
Also, the mean absolute error and the mean square error between 
observed and predicted values were calculated, using the same 
sample size, to measure the accuracy of the models. The adjusted 
coefficient of determination (adjusted R2) assessed the fit of 
the data to the statistical analysis. We also compared the predicted 
and observed values through visual inspection of the scatter-plot 
for the three time points.
Finally, we calculated the estimated means of CISI-PD in the 
time points and observed the linear trend through an analysis 
of co-variance for repeated measures, adjusting for the variables 
selected in the multilevel stepwise regression.
Table S2 in Supplementary Material summarizes the steps 
followed in data analysis. The SPSS version 22 was used for data 
analysis and Stata version 14 for predictive and multiple imputa-
tion models.
resUlTs
In the baseline sample (n = 389), 54.20% (n = 211) of patients 
were male, the mean age was 65.92 (SD: 11.15) years, and 80.50% 
(n = 313) were married. The mean years of education were 10.06 
(SD: 5.63), and 54% (n = 208) were retired. The average PD dura-
tion was 8.11 (SD: 6.00) years. About 5.9% of patients (n = 23) 
were treated with only levodopa, 20.4% (n = 79) with a dopamine 
agonist and 7.06% (n = 29) took both; the mean of LED was 547.4 
(SD: 371.62). The median HY staging was 2, and the distribu-
tion of the sample was as follows: stage 1, 25.20% (n = 97); stage 
2, 50.10% (n  =  193); stage 3, 19.50% (n  =  75); stage 4, 4.70% 
(n = 18); and stage 5, 0.50% (n = 2).
There were significant differences in age, baseline CISI-PD, and 
SCOPA-COG values between patients with complete or missing 
values (Table 1). Table 2 shows the changes in the clinical variables 
from baseline to time 3 experienced by the group that completed 
the study. The CISI-PD effect size between times 0 and 3 was 0.44.
The non-conditional or empty multilevel model of the CISI-PD 
dependent variable showed an ICC of 0.816. The MID model 
(Table 3) was established to estimate the disease global severity 
(as expressed by the CISI-PD) in times 1, 2, and 3. In addition 
to CISI-PD at baseline, the following baseline measures were 
statistical significant CISI-PD predictors: HADS, SCOPA-AUT, 
and SCOPA-COG. Disease duration, PPRSm, SCOPA-Sleep, 
EQ-VAS, EQ-5D index, SCOPA-Motor EM items bradykinesia, 
rigidity, tremor, and axial, age, and sex did not reach statistical 
significance.
The following formula describes the prediction model:
 
CISI-PD =Time +Time +LED
+HADS basel













0 523 4 684
+CISI PD Baseline
+× . . .  
This equation may be used to estimate the CISI-PD value of a 
person at follow-up. Take the example of a patient with a value of 
550 of LED, HADS value of 13, SCOPA-AUT of 20, SCOPA-COG 
of 25, and CISI-PD at baseline of 8. The value of CISI-PD, after 
1 year would be 8.589 (CISI-PDtime 1 = 0 × 0.648 + 0 × 1.405 +  
550  ×  0.002  +  13  ×  0.047  +  20  ×  0.043  −  25  ×  0.114  +  8  ×   
0.523 + 4.684); at 2 years 9.237 (CISI-PDtime 2 = 1 × 0.648 + 0 ×  
1.405 + 550 × 0.002 + 13 × 0.047 + 20 × 0.043 − 25 × 0.114 + 
8 × 0.523 + 4.684); and at 3 years 9.994 (CISI-PDtime 3 = 0 × 0.648 +  
1  ×  1.405  +  550  ×  0.002  +  13  ×  0.047  +  20  ×  0.043  −  25  ×   
0.114 + 8 × 0.523 + 4.684).
When the covariables described in this formula were entered 
into the empty model, the ICC was 0.563. All models showed 
comparable results in the sensitive analysis (Table 3). Figure 1 
shows similar results when comparing the prediction of the model 
and the data obtained, especially for CISI-PD values ranging 5–10 
(mild to moderate).
The estimated means of CISI-PD scores increased significantly 
between all yearly assessments (p < 0.001), following a significant 
linear trend (Figure 2).
DiscUssiOn
The CISI-PD is a measure of global PD severity; it is easy to apply, 
valid, reliable, accurate, and useful in both clinical practice and 
FigUre 1 | Observed and predicted values of Clinical Impression of Severity Index of Parkinson’s Disease from multilevel regression with multiple imputation, then 
deletion (MID).
TaBle 3 | Predictive models to estimate the patient’s degree of severity (expressed by the CISI-PD) at times 1, 2, and 3, from baseline values.
regression model with no missing data 
(n = 792)
Multiple imputation by chained equations 
(n = 1,167)
Multiple imputation, then deletion 
(n = 813)
β se p-Value 95% ci β se p-Value 95% ci β se p-Value 95% ci
Time (reference 1)
Time 2 0.621 0.157 <0.001 0.313 0.928 0.639 0.195 0.002 0.250 1.028 0.648 0.156 <0.001 0.341 0.955
Time 3 1.389 0.165 <0.001 1.065 1.712 1.316 0.257 <0.001 0.756 1.875 1.405 0.165 <0.001 1.081 1.729
LED baseline 0.002 0.001 <0.001 0.001 0.003 0.001 0.001 0.001 0.000 0.002 0.002 0.001 <0.001 0.001 0.003
HADS baseline 0.046 0.021 0.034 0.004 0.088 0.047 0.020 0.027 0.006 0.089 0.047 0.021 0.027 0.005 0.088
SCOPA-AUT total 
baseline
0.040 0.015 0.007 0.011 0.069 0.043 0.012 <0.001 0.020 0.067 0.043 0.015 0.003 0.014 0.071
SCOPA-COG 
baseline
−0.115 0.021 <0.001 −0.155 −0.075 −0.104 0.018 <0.001 −0.141 −0.068 −0.114 0.021 <0.001 −0.156 −0.072
CISI-PD baseline 0.530 0.041 <0.001 0.449 0.611 0.538 0.033 <0.001 0.472 0.604 0.523 0.040 <0.001 0.444 0.602
Constant 4.277 0.677 <0.001 2.951 5.603 4.249 0.647 <0.001 2.928 5.570 4.269 0.690 <0.001 2.913 5.624
MAE 2.100 2.115 2.103
MSE 7.208 7.287 7.210
Adjusted R2 0.525 0.517 0.526
β, coefficient of the regression model; 95% CI, confidence interval at 95% level; CISI-PD, Clinical Impression of Severity Index of Parkinson’s Disease; LED, levodopa equivalent dose; 
HADS, Hospital Anxiety and Depression Scale; SCOPA-AUT, SCOPA-autonomic scale; SCOPA-COG, SCOPA-Cognition scale; MAE, mean absolute error; MSE, mean square error; 
Adjusted R2, adjusted coefficient of determination.
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research. It provides a comprehensive assessment of important 
manifestations of PD not included in other global rating scales, for 
example, HY staging (4). The main objective of this study was to 
design a predictive model of the global severity of PD over 3 years 
using the CISI-PD, based on the clinical data obtained at baseline 
from a sample of patients with idiopathic PD. The model can comple-
ment knowledge about the evolution of PD progression over 3 years.
Our study showed that at the baseline, patients who com-
pleted the study were younger, with better baseline CISI-PD and 
cognitive function. These characteristics were similar to those of 
patients in another longitudinal study (28). To account for the 
sample loss, data imputation was used, with good results.
A PD global severity (CISI-PD) worsening of small magnitude 
was observed over the 3-year follow-up. On the one hand, this 
FigUre 2 | CISI-PD scores throughout the follow-up (3 years). Covariates at baseline appearing in the model are evaluated at the following values: LED = 496.77, 
HADS = 12.47, SCOPA-AUT = 19.24, and SCOPA-COG = 25.07. CISI-PD, Clinical Impression of Severity Index of Parkinson’s Disease; LED, levodopa equivalent 
dose; HADS, Hospital Anxiety and Depression Scale; SCOPA-AUT, SCOPA-autonomic scale; SCOPA-COG, SCOPA-Cognition scale. Significant linearity test  
(F statistic = 11.176, p-value = 0.001).
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small experienced deterioration may be due to the fact that PD 
worsening is slowed by the effect of anti-Parkinsonian medication 
(2, 29). On the other hand, it might indicate that the follow-up 
period was not long enough to detect larger changes in a disease 
with a slow and long progression.
In a previous study, the main cross-sectional determinants of 
CISI-PD were motor status (SCOPA-Motor Total), disease dura-
tion, depression and, to a lesser extent, age and comorbidity (5). 
In our longitudinal study, baseline values of PD global severity 
(CISI-PD), depression and anxiety symptoms (HADS), cognitive 
function (SCOPA-COG), autonomic symptoms (SCOPA-AUT), 
and LED were predictors of CISI-PD at 1, 2, and 3 years. A differ-
ent study design (cress-sectional vs. longitudinal) might explain 
the differences found in the factors associated to CISI-PD in both 
studies.
Several studies highlighted the importance of non-motor 
symptoms, such as cognitive impairment and autonomic dys-
function, in PD severity and progression. One study concluded 
that PD was associated with significantly higher morbidity rates 
associated with conditions such as mental and psychiatric, nerv-
ous system, gastrointestinal, genitourinary problems, among 
others (30). The presence of cognitive impairment was also 
associated with increased mortality (31) and a longer duration of 
disease increased the prevalence of dementia (32).
According to our results, the presence of the treatment as a 
predictor indicates its importance in Parkinson’s disease clini-
cal management (2, 33). In early stages of the disease, patients 
may not need anti-Parkinsonian treatment. In fact, although the 
l-DOPA is the most effective for the symptomatic treatment of 
PD, the presence of motor complications associated with this 
treatment, such as motor fluctuations and dyskinesias, is a limita-
tion that has led some physicians to advocate that the initiation 
of this treatment must be delayed (34). However, this treatment 
is necessary as PD progresses, which may partly account that its 
presence is associated with a higher score overall severity of PD.
The non-conditional or empty multilevel model of the CISI-PD 
yielded an ICC of 0.816. In other words, 81.6% of the variability 
observed in the CISI-PD was attributable to differences between 
individuals at baseline, and the remaining 18.4% was due to each 
individual’s evolution over time. The ICC dropped to 0.563 when 
the predictive model was adjusted by the significant covariables, 
which means that the 56.3% of the observed variability was 
attributable to differences between individuals at baseline and 
the remaining 43.7% was due to each individual’s evolution over 
time. These results imply that the disease progression depends 
more on the individual’s baseline characteristics than on the pas-
sage of time. Previous studies suggest that the rate of progression 
of PD symptoms and signs vary widely between different patients, 
according to their baseline characteristics (31). For instance, the 
presence of cognitive impairment at baseline has been associated 
with a faster progression of motor impairment (35).
The assessment of our results is subject to a number of limita-
tions. First, a loss of almost half of the patients over a period of 
only 3 years may result in less precise estimates. However, bias was 
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minimized with the use of multiple imputation techniques, with 
good results in sensitivity analysis (36). Second, the development 
of new concomitant diseases, expected in older age groups, was 
not taken into account. The third limitation is the relative short 
length of follow-up for a chronic condition as PD, which in our 
case lasted 3 years. Taken into account that some PD symptoms 
may appear later, new longitudinal studies over extended time 
span would be necessary (37). Fourth, we did not apply the 
predictive model in a different sample of our study, so we do not 
know how good are the predictions under real live conditions 
and in what extent the predictions could be superior to expert 
assumptions. For this reason, it would be appropriate to design 
new longitudinal prospective studies with a similar follow-up and 
compare the results of the assessments of each time point and the 
assumptions of the experts with those obtained with the predictive 
model. In addition, other studies could be carried out using differ-
ent endpoints focused, for instance, on non-motor complications 
such as cognitive impairment or impulse control disorders.
Despite such limitations, our results identify factors that influ-
ence PD progression. This might be of great value for clinicians 
for planning, implementation, and evaluation of intervention 
strategies to promote comprehensive rehabilitation and social 
inclusion of people with PD.
From our study, we can conclude that after the 3-year follow-up, 
a relatively short period, there was a PD global severity worsen-
ing of small magnitude. This study also showed that the baseline 
values of the overall degree of PD severity, cognitive function, 
depression and anxiety symptoms, autonomic symptoms, and 
LED were significant predictors of overall severity of PD at 1, 2, 
and 3 years. Our results can help toward a better understanding 
of the disease evolution in a short, 3-year period of PD global 
severity and to understand the role of non-motor symptoms such 
as depression, anxiety, autonomic, and cognitive symptoms, in 
the progression of the disease (30–32, 37).
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